Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 6
2024 2
2025 6
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Dahl D, et al. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. JAMA. 2022. PMID: 35133415 Free PMC article. Clinical Trial.
Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group. ...Mean HbA1c change from baseline was -2.11% with 5-mg tirzep …
Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide grou …
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
Billings LK, Winne L, Sharma P, Gomez-Valderas E, Chivukula KK, Kwan AYM. Billings LK, et al. Ann Intern Med. 2025 May;178(5):609-619. doi: 10.7326/ANNALS-24-03849. Epub 2025 Apr 4. Ann Intern Med. 2025. PMID: 40183678 Clinical Trial.
BACKGROUND: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for the treatment of adults with type 2 diabetes or obesity, showed clinically meaningful reductions in hemoglobin A(1c) (HbA(1c)) and …
BACKGROUND: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist appr …
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
Frias JP, De Block C, Brown K, Wang H, Thomas MK, Zeytinoglu M, Maldonado JM. Frias JP, et al. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1745-1753. doi: 10.1210/clinem/dgae038. J Clin Endocrinol Metab. 2024. PMID: 38252888 Free PMC article. Clinical Trial.
CONTEXT: In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and improved markers of insulin sensitivity and beta-cell function to a greater extent than comparators. ...CONCLUSION: In this post hoc analysis, …
CONTEXT: In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and imp …
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.
Gao L, Lee BW, Chawla M, Kim J, Huo L, Du L, Huang Y, Ji L. Gao L, et al. Nat Med. 2023 Jun;29(6):1500-1510. doi: 10.1038/s41591-023-02344-1. Epub 2023 May 25. Nat Med. 2023. PMID: 37231074 Clinical Trial.
The primary endpoint was non-inferiority of mean change in hemoglobin A1c (HbA1c) from baseline to week 40 after treatment with 10 mg and 15 mg of tirzepatide. Key secondary endpoints included non-inferiority and superiority of all tirzepatide doses in HbA1c …
The primary endpoint was non-inferiority of mean change in hemoglobin A1c (HbA1c) from baseline to week 40 after treatment with 10 mg …
Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
Osumili B, Fan L, Paik JS, Pantalone KM, Ranta K, Sapin H, Tofé S. Osumili B, et al. Diabetes Res Clin Pract. 2024 Jun;212:111717. doi: 10.1016/j.diabres.2024.111717. Epub 2024 May 21. Diabetes Res Clin Pract. 2024. PMID: 38777128 Free article. Clinical Trial.

Furthermore, all tirzepatide doses showed greater odds of patients achieving HbA1c targets of 6.5 % ( 48 mmol/mol) and < 7.0 % (<53 mmol/mol) and weight loss targets of 5 % and 10 %, versus semaglutide 0.5 mg. CONCLUSIONS: In these aITCs, glycated

…

Furthermore, all tirzepatide doses showed greater odds of patients achieving HbA1c targets of 6.5 % ( 48 mmol/mol) and < 7.0 % (

…
Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.
Pearson ER, Del Prato S, Pavo I, Franco DR, Zheng J, Nicolay C, Hemmingway A, Wiese RJ, Kahn SE. Pearson ER, et al. Diabetes. 2025 Oct 1;74(10):1850-1862. doi: 10.2337/db25-0276. Diabetes. 2025. PMID: 40633089 Free PMC article. Clinical Trial.
We found greater weight loss and improved beta-cell function were the main predictors for sustained glycemic control with tirzepatide therapy. No clinically relevant predictor was identified for sustained weight loss. Simple clinical measures ma …
We found greater weight loss and improved beta-cell function were the main predictors for sustained glycemic control with t …
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.
Bergman BK, Rosenstock J, Garvey WT, Batterham RL, Chen Y, Liu M, Sharma P, Karanikas CA, Thieu VT. Bergman BK, et al. Diabetes Obes Metab. 2025 Jun;27(6):3223-3232. doi: 10.1111/dom.16337. Epub 2025 Mar 13. Diabetes Obes Metab. 2025. PMID: 40083081 Free PMC article. Clinical Trial.
AIMS: This participant-level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight reductions with tirzepatide treatment in participants with type 2 diabetes (T2D) from the SURPASS programme. ...Continuous t …
AIMS: This participant-level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight …
HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.
Vilsbøll T, Malecki MT, Sharma P, Thieu VT, Chivukula KK, Kiljanski J. Vilsbøll T, et al. Diabetes Obes Metab. 2025 Oct;27(10):5498-5505. doi: 10.1111/dom.16592. Epub 2025 Jul 31. Diabetes Obes Metab. 2025. PMID: 40746012 Free PMC article.
To assess the contribution of weight loss (WL) to the observed glycaemic effect, we performed mediation analysis of three randomized, controlled, parallel, 4-arm SURPASS(S)-trials; 1, 2 and 5, for a total of 2831 participants. ...These results help to underst …
To assess the contribution of weight loss (WL) to the observed glycaemic effect, we performed mediation analysis of three rand …
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
Karimi MA, Gholami Chahkand MS, Dadkhah PA, Sheikhzadeh F, Yaghoubi S, Esmaeilpour Moallem F, Deyhimi MS, Arab Bafrani M, Shahrokhi M, Nasrollahizadeh A. Karimi MA, et al. Front Pharmacol. 2025 May 15;16:1438318. doi: 10.3389/fphar.2025.1438318. eCollection 2025. Front Pharmacol. 2025. PMID: 40444045 Free PMC article.
However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observed. ...Moreover, it presents advantages over Dulaglutide, specifically in lowering FBS levels. However, Tirzepatide surpasses …
However, weight loss (2.48; 95% CI: 0.45-4.51; p = 0.02) and reduced FBS levels (10.76; 95% CI: 0.55-20; p = 0.04) were observ …
Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.
Kubota M, Yamamoto K, Yoshiyama S. Kubota M, et al. Cureus. 2023 Oct 4;15(10):e46490. doi: 10.7759/cureus.46490. eCollection 2023 Oct. Cureus. 2023. PMID: 37800161 Free PMC article.
Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. ...However, exacerbation of blood glucose and rebound of weight gain occurred relatively early after administration was ended. For ty …
Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. …
15 results